Key result
ML390 inhibits EV71 replication and improves survival in infected mice.
Why the study?
Enterovirus 71 causes hand, foot, and mouth disease, but no effective antiviral drugs are available to treat it.
Does ML390 inhibit EV71 replication and improve survival in preclinical models of enterovirus 71 infection?
Does ML390 inhibit EV71 replication and improve survival in preclinical models of enterovirus 71 infection?
ML390 demonstrates potential as an antiviral agent against enterovirus 71 by inhibiting the de novo pyrimidine biosynthesis pathway.
ML390 shows preclinical antiviral activity against EV71; leaves open translation to human therapy.
Enterovirus 71 (EV71), a small, single-stranded, positive-sense RNA virus belonging to the enterovirus genus in the family Picornaviridae , causes hand, foot, and mouth disease. Although EV71 seriously threatens to public health , no effective antiviral drugs are available for treating this disease. In this study, we found that ML390, a dihydroorotate dehydrogenase inhibitor , has potential anti-EV71 activity. ML390 dose-dependently inhibited EV71 replication with IC 50 and selectivity index values of 0.06601 μM and 156.5, respectively. Supplementation with the downstream product orotate significantly suppressed the ability of ML390 to inhibit EV71 replication. Moreover, an adequate supply of exogenous uridine and cytosine suppressed the anti-EV71 activity of ML390. Thus, the antiviral activity of ML390 is mediated by the inhibition of the pyrimidine synthesis pathway. In an EV71-infected mouse model, ML390 reduced the load of EV71 in the brain, liver, heart, spleen, front legs, and hind legs, and significantly increased the survival rate of the mice infected by EV71. ML390 shows potential for the treatment of hand, foot, and mouth disease caused by EV71 infection.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2022) studied Enterovirus 71 infection. ML390 was evaluated on EV71 replication (IC50 0.06601 μM). ML390 inhibited EV71 replication with an IC50 of 0.06601 μM and significantly increased the survival rate of EV71-infected mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: